Athira pharma presents overview and update from act-ad and lift-ad trials of ath-1017 in mild-to-moderate alzheimer's disease at ctad conference

– balanced baseline characteristics in act-ad and lift-ad to date – – topline data from act-ad trial targeted for first half of 2022 –

ATHA Ratings Summary

ATHA Quant Ranking